News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Zacks Market update
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Arcturus Therapeutics Holdings Inc. (ARCT) saw a significant price increase of 23.12%, adding $2.54 to its stock value. The article provides live quotes and charts for ARCT but notes that there is no current analyst rating data or earnings information available for the company. โฆ
Arcturus Therapeutics stock (ARCT) surged nearly 20% due to positive sentiment surrounding its mRNA pipeline, including the regaining of global rights to its KOSTAIVE vaccine and a growing cash reserve of $191.5 million. Despite a slight revenue miss and continued losses in Q2, the โฆ
This article analyzes Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) using AI models, identifying strong near and mid-term sentiment but a weak long-term outlook. It highlights a significant risk-reward short setup and provides specific trading strategies (Long, Momentum Breakout, Risk Hedging) with entry, target, and โฆ
This article examines Arcturus Therapeutics Holdings' cash burn rate and its implications for the company's future. It highlights the company's current cash reserves and how long they might last given its operating expenses. The analysis is crucial for investors to understand the company's financial โฆ
Arcturus Therapeutics is focusing its mRNA platform on rare diseases like cystic fibrosis (CF) and ornithine transcarbamylase (OTC) deficiency, utilizing its vaccine business to fund these therapeutic developments. The company expects to decide on advancing its inhaled mRNA treatment for CF (ARCT-032) into Phase โฆ
H.C. Wainwright has reiterated its Hold rating on Arcturus Therapeutics (ARCT.US) and maintained its target price at $9. This indicates that the firm sees the stock as likely to perform in line with the broader market and does not anticipate significant price movement from โฆ
Wall Street Zen upgraded Arcturus Therapeutics (ARCT) from "strong sell" to "sell," while Weiss Ratings maintained its "sell (D-)" rating. Despite these downgrades, MarketBeat's analyst consensus remains a "Moderate Buy" with an average price target of $24.25. The clinical-stage biotech company, which develops mRNA โฆ
Arcturus Therapeutics (NASDAQ:ARCT) announced its quarterly earnings, reporting an EPS of ($0.84), beating analyst estimates by $0.16, despite revenue of $2.96 million falling short of expectations. The company provided updates on clinical trials for ARCT-810 and ARCT-032, and regained global rights to its KOSTAIVE โฆ
Arcturus Therapeutics Holdings Inc.'s average stock price target has been reduced from $20.6 to $20.2 by 10 analysts, still suggesting a significant 232% potential upside based on its closing price on August 6. Despite the target cut, the consensus rating from 13 analysts remains โฆ
CCORF has reiterated its Buy rating for Arcturus Therapeutics (ARCT.US) but has adjusted its target price downwards to $20. This indicates a continued positive outlook on the stock, albeit with a revised valuation.
Arcturus Therapeutics reported its Q2 2026 financial results and provided updates on its pipeline, including continued progress in the ARCT-032 Phase 2 cystic fibrosis study and completed enrollment for the ARCT-810 Phase 2 OTC deficiency study. The company regained global rights to KOSTAIVEยฎ and โฆ
Arcturus Therapeutics reported a narrower-than-expected loss for Q2 2026, beating EPS forecasts by 20%, but saw a significant revenue drop due to the conclusion of its CSL Seqirus collaboration. The company emphasized progress in its rare disease pipeline, including cystic fibrosis (ARCT-032) and ornithine โฆ
Arcturus Therapeutics Holdings Inc. (ARCT) reported its Q2 2026 financial results, with revenue of $2.96 million and a net loss of $23.79 million, resulting in a diluted loss per share of $(0.84). This decline in revenue is attributed to KOSTAIVE transitioning to commercial stages, โฆ
Arcturus Therapeutics (ARCT) reported a Q2 loss of $0.84 per share, surpassing the Zacks Consensus Estimate of a $1.07 loss, and beat revenue estimates with $2.96 million. Despite underperforming the S&P 500 year-to-date, the company has exceeded EPS estimates in three of the last โฆ
The article discusses the critical price action for Arcturus Therapeutics Holdings Inc. (ARCT) for tactical trading, highlighting a near-term strong sentiment that could challenge persistent mid and long-term weakness. It identifies an exceptional 394.0:1 risk-reward setup targeting a 90.6% gain versus 0.2% risk and โฆ
Arcturus Therapeutics Holdings Inc (ARCT) is anticipated to report a loss of 100 cents per share in its upcoming earnings. This forecast is part of an earnings preview, suggesting investors and analysts are closely watching the company's financial performance. The full article provides more โฆ
PTC Therapeutics (PTCT) came out with quarterly earnings of $0.92 per share, beating the Zacks Consensus Estimate of a loss of $0.17 per share. This compares to a loss of $0.83 per share a year ago. These figures are adjusted for non-recurring items. This โฆ
This article provides a risk assessment for Arcturus Therapeutics Holdings Inc (ARCT), detailing its volatility, financial risk, and investment risk. It highlights the company's current risk assessment score, its beta value compared to the S&P 500 index, and various financial metrics such as maximum โฆ
Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) announced it will release its second-quarter financial results for 2026 on Thursday, August 6th, after market close. The company will also host a conference call and webcast at 4:30 p.m. Eastern Time on the same day to provide โฆ
Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) is scheduled to release its Q2 2026 financial results after market close on August 6, 2026, followed by a conference call at 4:30 p.m. ET for a corporate update. While no specific financial figures are in the pre-announcement, โฆ
Search by ticker symbol or company name and select a result to open its chart.
Start typing to find a stock or ETF.
Choose one or more countries for market search, or include every covered market.
Currently searching United States